UCLA research finds that combining immunotherapy with chemotherapy is safe and effective for people with advanced small cell cancers in the bladder and prostate.
t-NEPC is an aggressive subtype of metastatic castration-resistant prostate cancer (mCRPC), and prior clinical trials with HER2-targeted therapies for mCRPC have failed to show...